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Abstract
Background: In humanitarian settings common mental disorders (depression, anxiety disorders, posttraumatic stress
disorder) are highly prevalent. The World Health Organization (WHO) has developed Problem Management Plus (PM+),
a 5-session, individual psychological intervention program, delivered by paraprofessionals that addresses common
mental disorders in people in communities affected by adversity. The objectives of this study are to test effectiveness
and cost-effectiveness of the locally adapted PM+ compared to Treatment as usual (TAU) in Peshawar District, Pakistan.
Methods: A randomised controlled trial will be conducted in 346 primary care attendees in 3 health care centres in
Peshawar District, Pakistan. After informed consent, primary care attendees with high levels of psychological distress
according to the General Health Questionnaire-12 (GHQ-12) and functional impairment (WHO Disability Assessment
Schedule 2.0 (WHODAS)) will be assigned to PM+ (n = 173) or TAU (n = 173). At baseline, 1 week and 3 months
following PM+, independent assessors will assess psychological distress with the Hospital Anxiety and Depression
Scale (HADS), and functional disability with the WHODAS. Secondary outcomes are posttraumatic stress disorder (PTSD)
symptoms, and client-perceived priority problems. Further, cost-effectiveness will be assessed using the Service Receipt
Inventory (SRI).
Discussion: If proven effective, PM+ will be rolled out to other areas for further adaptation and testing in diverse
humanitarian settings.
Trial registration: ACTRN12614001235695. Registered 26 November 2014. Australian New Zealand Clinical Trials Registry
Background
Over the past 3 decades the north-western Pakistani prov-
ince of Khyber Pakhtunkhwa, with Peshawar as its capital,
has been affected by political instability, economic uncer-
tainty, regional conflict, and continuous daily violence [1].
In such settings, common mental disorders are highly
prevalent [2]. In Pakistan alone, the estimated prevalence
of common mental disorders ranges between 10 and 16 %
[3] and major depression is one of the major causes of dis-
ability [4]. These mental health conditions impair basic
functioning required for survival and livelihoods. Accord-
ingly, there is a great need for effective psychosocial inter-
ventions that can reduce symptoms of common mental
disorders and improve daily functioning.
A major obstacle to addressing the mental health chal-
lenges in many humanitarian settings is that they occur
in low and middle income countries (LMICs). LMICs
typically lack sufficient numbers of specialized mental
health care professionals, have poor systems to deliver
evidence-based interventions, and cannot afford costs
associated with intensive treatment programs [5]. Al-
though psychological interventions, such as cognitive be-
havioural therapy (CBT), are effective in the treatment
of common mental disorders that are evident in the
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wake of adversity [6, 7], these typically require expert
mental health professionals providing treatments that are
usually lengthy and costly to the health service. Overall,
there is little evidence for treating mental health condi-
tions in humanitarian settings [2], and the trials that have
been conducted have focused on treatments for posttrau-
matic stress disorder (PTSD) [2]. Limitations of this ap-
proach are that PTSD treatments are usually relatively
intensive and lengthy, and individuals affected by adversity
and trauma typically have a range of other problems than
PTSD, including depression and anxiety [2].
For interventions to be scalable in LMIC settings, they
should be of short duration and sufficiently simple that
they can be carried out by lay people in the community [8],
and they should address a broad range of mental and
psychosocial health problems relevant to communities
affected by adversity. To meet these demands, WHO has
developed a low-intensity 5-sessions program termed
Problem Management Plus (PM+) which may be delivered
by trained lay people [9]. This program is aimed at redu-
cing symptoms of depression, anxiety, PTSD, stress in the
wake of adversity and trauma. It comprises evidence-based
techniques: of (a) problem solving, (b) stress management,
(c) behavioural activation, and (d) accessing social support.
Although developed following considerable international
consultation, the WHO has adopted the position that im-
plementation of the protocol should not occur until it has
been proven to be effective via controlled trials in LMICs.
To this end, this paper provides an overview of the trial
protocol for the initial study of PM+ in the Peshawar
District. The PM+ manual has been translated into Urdu
and adapted to the local culture in the Peshawar District.
Qualitative methods including free listing and key inform-
ant interviews [10] identified priority problems and health
concepts from local perspectives which were used to
inform intervention adaptation. Subsequent to this process,
this study aims to (a) evaluate the effectiveness of the
locally adapted version of PM+ in Peshawar in reducing
symptoms of common mental disorders; and (b) evaluate
the cost-effectiveness of PM+ in this setting.
Methods
Design
The study is a randomised controlled trial (RCT) that
compares PM+ to treatment as usual (TAU) in primary
care attendees in three primary care centres in Peshawar
District, Pakistan. The primary outcomes are psycho-
logical distress in terms of states of anxiety and depression
at 20 weeks after inclusion. Secondary outcomes are func-
tional disability, PTSD symptoms, and cost-effectiveness.
Participants
Participants will include primary care attendees who ful-
fil the following inclusion criteria: (a) score above 2 on a
screening questionnaire for common mental disorders
(General Health Questionnaire-21; GHQ-12) [11, 12]
and (b) score above 16 on a screening questionnaire for
functional impairments (WHO Disability Assessment
Schedule 2.0; WHODAS) [13].
Exclusion criteria are: (a) suicide risk as defined in the
mhGAP Intervention Guide [14]; (b) individuals with a
severe mental disorder (e.g., psychotic disorders, sub-
stance dependence) or severe cognitive impairment (e.g.,
severe intellectual disability or dementia), based on defi-
nitions in the mhGAP Intervention Guide [14].
Procedure
The study will be carried out in three peri-urban primary
healthcare centres (PHCs) in Peshawar District in
Pakistan, overseen by staff of Lady Reading Hospital. All
research assessments and PM+ sessions are conducted at
the PHCs. The study flow diagram is presented in Fig. 1.
Potential participants are informed about the study.
Informed consent entails a two-step procedure: 1. In-
formed consent for screening and 2. Informed consent
for taking part in the PM+ trial. The latter is only re-
quired for participants meeting inclusion criteria. For
each step respondents who decide to participate will be
asked to complete a written consent form. For partici-
pants who are illiterate, witnessed oral consent and a
thumb print in lieu of a signature will be asked, in line
with recommendations from WHO [15]. The witness
will be any staff member of at the PHC (except the
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medical officer or health care professional involved dir-
ectly in the care of the patient in order to avoid potential
explicit or implicit coercion); or any adult person not re-
lated to the participant who the participant is comfort-
able having present during consent.
Following informed consent for screening, a research as-
sistant will record demographic characteristics and partici-
pants will be administered the GHQ-12, the WHODAS,
and the suicide screening questions. If they are not at
imminent risk of suicide, do not meet other exclusion cri-
teria, and score above both the cut-offs of the GHQ-12
and the WHODAS, they will be provided informed con-
sent information about the RCT. At least 24 h later, a re-
search assistant will conduct the pre-trial assessment,
which will comprise the Hospital Anxiety and Depression
Scale (HADS) [16, 17], the Patient Health Questionnaire
(PHQ-9) [18], the Harvard Trauma Questionnaire (HTQ)
[19] events list, Life Events List for Pakistan (LELFP) [20],
the PTSD Checklist for DSM-5 (PCL-5) [21], the Psycho-
logical Outcome Profiles instrument (PSYCHLOPS) [22]
and the Service Receipt Inventory (SRI) [23].
If participants are not selected because they score
below the cut-offs for the GHQ-12 or the WHODAS,
they will be provided feedback on their test outcomes
and reasons why they are not eligible for the study will
be explained to them.
The post-intervention assessment (WHODAS, HADS,
PHQ-9, PCL-5, HTQ events list, LELFP, PSYCHLOPS)
will be scheduled 7 weeks after the pre-intervention as-
sessment (i.e., 1 week after the 5th PM+ session), and the
follow-up assessment (WHODAS, HADS, PHQ-9, PCL-5,
HTQ events list, LELFP, PSYCHLOPS, SRI) will be sched-
uled at 13 weeks after the post-intervention assessment
(i.e., 20 weeks after inclusion, in line with the timing of
the follow-up assessment for the PM+ participants). The
participants who receive PM+ will also be administered
the PSYCHLOPS by the lay-counsellor at the beginning of
each PM+ session.
All assessments will be delivered in interview format as
many participants are expected to be illiterate. All instru-
ments will be administered by independent assessors blind
to the allocation status of the participants. All assessors
have received a 2-day training covering administering the
instruments, common mental disorders, general interview
techniques, and ethical research conduct. Ongoing moni-
toring of assessors’ competency will be conducted through
regular supervision by the trial manager.
Sample size
A total number of 346 participants will be included in
this study. Since we are not aware of similar intervention
studies that have been carried out in this population,
and we expect the population to be heterogeneous with
respect to the types of common mental disorders, we
aimed for a relatively conservative estimate of a 50 % re-
duction in HADS overall score in the PM+ group as
compared to a 30 % reduction in the control group at
3 months follow-up (this estimate was extrapolated from
a trial involving lay workers in India) [24]. This corre-
sponds with an odds ratio for the PM+ program of 2.3.
Power calculations suggest a minimum sample size of
133 participants per group (power = 0.95, alpha = 0.05,
two-sided). Taking into account an expected 30 % attri-
tion at 3 months follow-up, we aim to include a total
number of 346 participants (173 in the PM+ group and
173 in the TAU control group).
Randomisation
Randomisation will occur following pre-assessment. This
will be conducted by an independent research assistant lo-
cated off-site (Human Development Research Foundation,
Islamabad, Pakistan) and not involved in the delivery of
PM+, clinical supervision, assessments or other aspects of
the day-to-day running of the study. Randomisation will
be performed using computerized software on a 1:1 basis.
Participants randomised into the PM+ condition will be
allocated to a PM+ lay-counsellor by the same independ-
ent researcher who performed the randomisation. This
lay-counsellor will plan five consecutive meetings with the
participant, with the first session being scheduled no lon-
ger than 1 week after the pre-intervention assessment.
PM+
Developed by WHO, PM+ is a new, brief, psychological
intervention program based on established problem-
solving and behavioural therapy techniques [9]. The
program consists of 5 weekly sessions lasting 90 min.
Session one orients participants to the program with
motivational interviewing techniques to improve en-
gagement, provides psychoeducation about common
reactions to adversity, and teaches participants a basic
stress management strategy. The latter strategy is prac-
ticed at the conclusion of every subsequent session to
enhance learning. Session two addresses a participant-
selected problem through the provision of problem
solving techniques and introduces commencement of
behavioural activation procedures. Sessions three and
four continue to support participants’ application of
problem solving, behavioural activation, and relaxation
exercises, and introduces strategies to strengthen social
support networks. In session five, education about
retaining treatment gains is given, all learned strategies
are reviewed, and the program is finished. For a more
detailed description of the development of the manual,
see Dawson et al. [9].
PM+ providers are male and female lay-counsellors who
will have received 8 days of training in basic counselling
skills and delivery of PM+ (inclusive of 6-day initial
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training and a 2-day refresher training before the start of
the trial). Weekly supervision will be provided by three su-
pervisors who have received an additional 1-day intensive
training in supervisory techniques. In addition, supervisors
will receive monthly supervision with the PM+ master
trainer, a clinical psychologist (KD), to ensure treatment
adherence and provide support. Treatment fidelity will be
ensured by an independent assessor who has been trained
in PM+. Independent assessors will also directly observe a
sample of 10 % of lay-counsellor’s sessions and will system-
atically assess which elements of the program have been
carried out by the PM+ provider using a checklist.
Treatment-as-usual (TAU)
TAU in primary healthcare centres in Peshawar for com-
mon mental disorders usually consists of no treatment, or
a range of alternate treatment regimes, such as vitamin in-
jections; evidence-based mental health care is currently
not available in PHCs. For this study, participants in the
TAU condition will be referred to their primary care phy-
sicians for treatment. These primary care physicians will
receive the standard training in treatment of common
mental disorders that is routinely taught by the Lady
Reading Hospital. If, during this treatment or during the
study’s assessments participants in TAU arm show severe
psychiatric disorders (e.g., psychosis) or problems (e.g.,
imminent suicidality) that require immediate specialist
treatment and follow-up, they will be referred to a psych-
iatrist within the Lady Reading Hospital.
Throughout the study, we will carefully keep track of
the types and amount of support participants receive
through the SRI instrument (see measures section below).
Screening measures
Risk of suicide and presence of severe psychiatric symp-
toms as defined by the International Statistical Classifi-
cation of Diseases and Related Health Problems-10th
revision (ICD-10) [25] will be assessed using the assess-
ment tools consistent with the mhGAP Intervention
Guide [14].
The WHODAS [13] is a generic assessment instrument
assessing health and disability. Simple to administer, it is
applicable across all health states, including mental disor-
ders, and across cultures. The WHODAS assesses difficul-
ties people have due to their illness across six domains of
functioning (cognition, mobility, self-care, getting along,
life activities, and participation). Difficulties are scored
over the last 30 days on a five-point Likert scale as none,
mild, moderate, severe, or extreme. The 12-item inter-
viewer administered version will be used in this study.
The GHQ-12 [11, 12] assesses level of general psycho-
logical distress during screening. It consists of 12 ques-
tions that are scored on a four-point Likert scale ranging
from 0 to 3. When used as a screening tool, the GHQ-
12 is usually scored bi-modally (i.e.,-0-0-1-1)., and the
total score ranges between 0 and 12, with higher scores
representing higher levels of distress. In previous studies
in Pakistan, cut-offs of 1 or higher and 2 or higher have
been reported and used for determining clinical caseness
of common mental health disorders [12, 26, 27].
Primary outcomes
In addition to the WHODAS, psychological distress in
terms of states of anxiety and depression is measured
using the HADS [16, 17]. The HADS is a well-established
14-item scale consisting of two sub-scales: HADS-A (anx-
iety, seven items, range 0–21) and HADS-D (depression,
seven items, range 0–21). Higher scores indicate more
anxiety and/or depression. The Urdu version of the HADS
showed satisfactory reliability and validity [17].
Secondary outcomes
The PHQ-9 is nine-item instrument measuring presence
and severity of depression during the past 2 weeks [18].
The PHQ-9 questions are derived from the 16-item ver-
sion. Participants rate their responses on a four-point
Likert scale ranging from “not at all” to “nearly every
day”. The the PHQ-9 total severity score ranges from 0
to 27. The PHQ has been validated in Urdu [28, 29].
DSM-5 posttraumatic stress disorder (PTSD) symp-
toms during the past week will be measured using the
PCL-5 [21], which is a 20-item checklist. Items are rated
on a 0–4 scale and add up to a total severity score of 80.
The previous version of the PCL based on DSM IV
PTSD symptoms, the PCL-C, has been used previously
in Pakistan [30] and has been found to have acceptable
psychometric properties (Mushtaq, unpublished data,
2013). The PCL-5 will be adapted to ask for symptoms
in the last week (rather than month) to enhance sensitiv-
ity to change.
Finally, PSYCHLOPS [22] assesses progress on problems
for which the person seeks help. It consists of four ques-
tions that encompass three domains: problems (2 ques-
tions), functioning (1 question) and wellbeing (1 question).
Participants are asked to give free text responses to the
problem and function domains. Responses are scored on
an ordinal six-point scale producing a maximum score of
18 (six points per domain). The PSYCHLOP version
administered at posttreatment and follow-up also includes
an overall valuation question (determining self-rated out-
come ranging from “much better” to “much worse”). PSY-
CHLOPS has been validated in primary care populations
across several countries [31, 32].
Other measures
To assess the experience of potentially traumatic events,
part one of the HTQ [19] will be administered. This in-
cludes 17 items describing a range of traumatic events,
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such as: “lack of food and water”, “forced separation
from family members”, and “being close to death”. Each
event is rated as either present (1) or absent (0). The
HTQ has been validated and applied in many countries,
including Pakistan [33].
Life events other than potentially traumatic events
(e.g., loss of job, housing problems, financial difficulties,
problems with the law, marital problems, bereavement,
etc.) are assessed using a life events measure previously
developed for the Pakistani population (LELFP [20]). Life
events are rated as either present (1) or absent (0).
Economic evaluation
The Service Receipt Inventory (SRI) assesses service
utilization during the time preceding the assessment and
related characteristics of people with mental disorders,
as the basis for calculating the costs of care for mental
health cost-effectiveness research [23]. It has been previ-
ously used in Pakistan and India [23, 34].
Adverse events reporting
All adverse reactions and serious adverse events (SAEs)
that are reported spontaneously by the participant or ob-
served by the investigators or other staff members dur-
ing the trial will be recorded by the research team and
will be reported to the local independent advisory board.
The chair of the advisory board will review SAEs within
48 h and the advisory board will review all AEs twice a
month, where necessary determining any appropriate ac-
tion in respect of ongoing trial conduct. The consent
process includes informing participants whom they can
contact if they become distressed or are displeased with
any aspect of the study.
Depending on the nature of the adverse event, follow
up may require additional tests or medical procedures as
indicated, and/or referral to the general physician or a
medical specialist. All adverse events will be followed
until specialist care (including referrals, additional tests
or medical procedures) is in place for the client, or until
a stable situation has been reached.
The principal investigator will inform the participants
and the local independent advisory board if anything oc-
curs, when it appears to the project group that the dis-
advantages of participation may be significantly greater
than was foreseen.
Analysis plan
To determine comparability between the conditions at
baseline, multiple planned comparisons will be conducted
for continuous variables and chi-squared tests for categor-
ical ones.
Hierarchical linear modelling (HLM) analysis will be
carried out to assess differential change over time in mean
HADS anxiety, depression and total score, WHODAS,
and PCL scores between groups. For each outcome, the
effects of time of measurement, group, and the group-by-
time interaction will be analysed. We will add the follow-
ing covariates at baseline to examine subgroup effects:
gender, education, and severity of symptoms. HLM pre-
sumes intent-to-treat analyses as HLM allows the num-
ber of observations to vary between participants and
effectively handles missing data. Time (linear and quad-
ratic), treatment condition, and their interaction will be
included in the models. Fixed effects parameters will be
tested at 95 % CI. The Level 1 model will represent
within-patient change over time, and the Level 2 model
will predict variation in within-patient change over time
and encompass between-patient variables.
We will also analyse aggregated health care costs, com-
puted from costs of treatment (primary care, outpatient
hospital visits, impatient admission, diagnostic tests and
investigations, drug prescriptions), and the aggregated
patient and family costs (number of days with reduced
working hours, informal caregiving time by relatives or
friends), and travel costs and time spent travelling to or
waiting for consultations. Cost data will also be analysed
using HLM, analysing effects of time of measurement,
group, and the group-by-time interaction on aggregated
health care costs and patient and family costs.
Descriptive analyses will be carried out in SPSS and
HLM analyses in Stata version 11.2. Across all analyses,
two-tailed tests will be reported with Cronbach alpha = .05.
Ethics
The project has been approved locally by the Institutional
Review and Ethics Board of the Postgraduate Medical
Institute, Lady Reading Hospital, Peshawar, Pakistan and
by the WHO Ethical Review Committee (Protocol ID:
RPC627, January 20, 2015).
Discussion
This RCT examines the effectiveness and cost-effectiveness
of PM+ in Peshawar, Pakistan. PM+ is a brief transdiagnos-
tic psychological intervention delivered by paraprofes-
sionals for people in low-income communities affected by
adversity. It aims to fill an urgent need by providing an
evidence-based low-intensity mental health intervention
that is amenable to LMICs. A second RCT on the effect-
iveness of individually delivered PM+ is planned to be car-
ried out in women affected by adversities in Nairobi,
Kenya. A third RCT on the effectiveness of group delivered
PM+ is planned to be carried out Swat, Pakistan. If proven
effective, PM+ may not only be used in similar areas in
Pakistan, but rolled out to other affected areas for further
adaptation and testing in diverse humanitarian settings.
The PM+ manual, if proven effective, will be published by
WHO and will be made available (with accompanying
training materials) for free on WHO’s website.
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